Rhyannon Spangler

TL;DR: Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models and outperformed the small-molecule lysyl oxidase inhibitor β-aminoproprionitrile.

TL;DR: It is shown that selective inhibition of MMP9 did not induce musculoskeletal syndrome in a rat model, but did reduce disease severity in a dextran sodium sulfate-induced mouse model of ulcerative colitis, and that inhibition of either tumor- or stroma-derived M MP9 was sufficient to reduce primary tumor growth.

TL;DR: Administration of the LOXL2-neutralizing antibody AB0023 inhibited bFGF-induced angiogenesis in Matrigel plug assays and suppressed recruitment ofAngiogenesis promoting bone marrow cells, suggesting that inhibition of LOXL1 may prove beneficial for the treatment of angiogenic tumours.

TL;DR: It is suggested that LOX and LOXL2 may play an important role in the pathogenesis of AMD, by reducing angiogenesis and inflammation, as well as fibrosis, in mice treated with either M64 or AB0023.

TL;DR: In this paper, methods and compositions for preventing and treating pulmonary fibrotic disorders, and for reducing or reversing the symptoms of idiopathic pulmonary fibrosis, such as pulmonary cancer, were presented.